Loading...
•
Sep 30, 2021
Abbott Q3 2021 Earnings Report
Achieved strong double-digit earnings growth and raised guidance.
Key Takeaways
Abbott announced strong growth overall and across all four of its major business areas in Q3 2021. The company is pleased with the continued advancements of its new product pipeline, including several recent launches in large, high-growth markets.
Worldwide sales increased 23.4 percent on a reported basis and 22.4 percent on an organic basis.
Global COVID-19 testing-related sales were $1.9 billion.
FreeStyle Libre® and Libre Sense™ sales were $968 million, representing sales growth of 41.6 percent on a reported basis.
Abbott projects 2021 diluted earnings per share from continuing operations under GAAP of $3.55 to $3.65.
Forward Guidance
Abbott projects 2021 diluted earnings per share from continuing operations under GAAP of $3.55 to $3.65. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be $5.00 to $5.10 for full-year 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...